Table 4.
Outcome (measure) | No of patients | Estimate (95% CI) | P value* | |
---|---|---|---|---|
As randomised (intention to treat) | Complier average causal effect (CACE) | |||
OR for mortality† | 498 | 0.62 (0.43 to 0.88) | 0.53 (0.34 to 0.84) | 0.008 |
OR for any reintervention related to the aneurysm | 502 | 1.12 (0.76 to 1.65) | 1.16 (0.69 to 1.94) | 0.58 |
EQ-5D‡ | 262 | 0.013 (−0.069 to 0.096) | 0.041 (−0.112 to 0.193) | 0.75 |
QALYs§ | 502 | 0.229 (0.043 to 0.414) | 0.512 (0.084 to 0.940) | 0.016 |
Total cost (£) | 502 | −2610 (−6200 to 978) | −6126 (−14336 to 2083) | 0.154 |
Incremental net benefit (£) | 502 | 9484 (2828 to 16 140) | 21 528 (5999 to 37 057) | 0.003 |
OR=odds ratio.
*Same for intention to treat and CACE estimates, but magnitude of effect might be different.
†4 patients lost to follow-up for mortality by 3 years.
‡For EQ-5D-3L scores, number of patients is total number eligible for follow-up (that is, still alive and not lost to follow-up). EQ-5D missing for 33 (22%) EVAR patients and 21 (19%) open repair patients.
§Includes patients who died.